TODAY'S MARKET INTELLIGENCE
Hengrui Medicine Subsidiary Receives Clinical Trial Approval Notice for HRS-3095 Tablets
English summary
Hengrui Medicine's subsidiary has received the clinical trial approval notice for HRS-3095 tablets, indicating smooth progress in new drug R&D and positive implications for long-term development.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence